HOME OUR DOCTORS VISITING OUR PRACTICE OUR LOCATIONS RESOURCES FOR DOCTORS CONTACT US PATIENT SIGN IN

Latest Blog Articles by See Clearly Vision

Ravens defensive tackle Brandon Williams seeing more clearly after surgery to combat eye condition

Created on: Wednesday, March 14, 2018

Baltimore Ravens defensive tackle, Brandon Williams, receives FDA approved collagen cross-linking treatment for both eyes due to his struggle with keratoconus. Performed by our very own Dr. Rajesh Rajpal, the treatment will help combat his condition to help him see clearly on the field. The Baltimore Sun shares his story:  

 http://www.baltimoresun.com/sports/ravens/ravens-insider/bs-sp-ravens-brandon-williams-eye-condition-0310-story.html

 

 

 

See Clearly Vision 2017 Winter Newsletter

Created on: Friday, December 08, 2017

 

 

 

Top 10 Questions about Corneal Cross-Linking

Top 10 Questions about Corneal Cross-Linking

Created on: Friday, November 03, 2017
Bryan Ross

Keratoconus is one of the most common corneal disorders in the U.S. today. In 2016, the FDA approved the corneal cross-linking procedure for progressive keratoconus and corneal ectasia after refractive eye surgery. Our very own Dr. Dawn Williams wrote an article in Optometry Times answering the top 10 frequently asked questions about corneal cross-linking: 

 http://optometrytimes.modernmedicine.com/optometrytimes/news/top-10-questions-about-cross-linking

 

 

Introducing Raindrop® Near Vision Inlay, a Simple Solution for Near Vision Loss

Introducing Raindrop® Near Vision Inlay, a Simple Solution for Near Vision Loss

Created on: Monday, July 31, 2017
Jessica Alvarez

 

Raindrop Vision Procedure Designed for People Who Want to Reduce or Eliminate Reading Glasses Now Available at   See Clearly Vision

 

 

The all-new Raindrop ® Near Vision Inlay is designed to improve near vision so you can see fine print, menus and your phone without the hassle of reading glasses
 
 

Tysons, July 31, 2017 -- If you are at the age where you need reading glasses to see your phone or read a newspaper, menu, or computer screen, See Clearly has exciting news to share! We would like to introduce to you the new Raindrop procedure.

 

Raindrop is the world’s first inlay to change the shape of the cornea (the clear, front part of the eye) to improve near vision and it is designed to help reduce or eliminate the need for reading glasses. The outpatient procedure takes about 10 minutes and patients return to most of their daily activities the next day.



Raindrop is receiving a great deal of interest with the recent FDA approval in June of 2016. But how does it work? Who is it right for? We understand many people have questions about Raindrop, so here are some answers to frequently asked questions.

Who should consider the Raindrop Near Vision Inlay?

Age related loss of near vision or presbyopia is the condition that leaves many of us reaching for reading glasses in our 40’s and early 50’s. Anybody who needs reading glasses for daily tasks such as using mobile phones, reading a menu, fine print or doing close-up work may be a candidate.

What causes this condition?

Presbyopia, or age related loss of near vision, happens when your lens loses elasticity, making it difficult to change your focus to see objects up close. Everyone -- yes, everyone -- will eventually develop presbyopia.

How effective is the Raindrop Near Vision Inlay procedure?

Most people who have had the Raindrop implanted, see an improvement in their near vision by one week and it continues to improve for several weeks. Patients need to use eye drops for several months for comfort and healing.1

What is the inlay, exactly?

It is a tiny disc, about the size of a pinhead. It is comprised of approximately 80 percent water and is placed just beneath the surface of the eye. It works by gently changing the central curvature of the cornea, clear front part of the eye. 




How long does it take?

The procedure usually takes up to 10 minutes.

Is it painful?

Numbing drops are given for the procedure, but most patients do not experience any pain.

Does it have to be done with LASIK?

No, it is designed to be performed without LASIK. The procedure does require the use of an ophthalmic laser to create a LASIK-like flap just beneath the surface of the eye.

 

What is the Raindrop Near Vision Inlay made of?

It is a soft, biocompatible material, similar to a soft contact lens, which has similar properties and water content as the cornea.

Does it interfere with far vision?

One Raindrop Near Vision Inlay is placed in the cornea of the non-dominant eye. Both eyes work together to create one image. The near vision is improved in the Raindrop eye, while the distance is slightly affected.  With both eyes working together there is not a compromise for distance vision and patients still have a significant improvement in near vision.

Is it safe for the eye?

Extensive trials and usage show that it is safe. This was confirmed by the US FDA. Raindrop is bioengineered to facilitate the transport of nutrients and fluid to the eye.

Will people know I am wearing one?

 

No. It is transparent, so no one will realize there is a Raindrop in your eye. 



How does it work in low light?

Very well. Since Raindrop is transparent 99.7% of light passes through the inlay reaches the back of the eye where the image is processed.1 Raindrop offers patients good performance in all lighting conditions.

Can the inlay ever be removed?

Yes, the Raindrop can be removed and most patients go back to their vision before Raindrop.1

 

How can I find out more?

Short video of how Raindrop works: https://www.youtube.com/watch?v=LuVUlDICGmc

 

Find out if you are a candidate for Raindrop:

https://www.youtube.com/watch?v=IGvA8AKF_Cw


For more information: the experts/surgical counselors at See Clearly Vision will be glad to answer any further questions [703-827-5454] or if you would like to schedule a consultation, contact us here: https://www.seeclearly.com/tysons-corner/contact-us.htm

 

1.       Raindrop Near Vison Inlay Prescribing Label, ReVision Optics, Inc.

 

Please see Professional Use Information and/or Patient Information Brochure for a complete list of Potential Risks, Warnings and Precautions. www.raindropinlay.com

 

 

 

Tales from Los Angeles

Tales from Los Angeles

Created on: Monday, July 10, 2017
Christina Appleman, COMT

During the first weekend in May, a very important event took place in Tinseltown. It wasn’t a movie premiere or a celebrity plugging their latest product. In fact, it was much more exciting! The annual American Society of Cataract and Refractive Surgery (ASCRS) meeting took place in Los Angeles. While there, our very own Dr. Rajesh Rajpal hosted an event on Corneal Collagen Cross-Linking.

An expert panel of doctors was assembled to discuss the science, implementation, and future of Collagen Cross-Linking. Collagen Cross-Linking is used to treat eyes with progressive keratoconus, a condition in which the normally round cornea thins and bulges outward into a cone shape. Cross-Linking can also be used in individuals who experience ectasia after refractive surgery. Ectasia occurs when the inner layers of the cornea become weak, causing the cornea to change shape, protrude forward, and distort vision.

As the Chief Medical Officer of Avedro, which has produced the only FDA approved Corneal Collagen Cross-Linking device in the United States, Dr. Rajpal hosted and moderated the Cross-Linking event co-sponsored by Avedro and the Cornea Society. It was noted during this event that since its approval approximately one year ago, there are 1,500 Cross-Linking systems in the U.S. and over 250,000 treatments have been performed. See Clearly Vision is proud to be one of the first and primary practices to conduct the clinical trials for approval of Corneal Collagen Cross-Linking. To learn more about Collagen Cross-Linking, please call 703-827-5454 to schedule an appointment today. 

To see the Los Angeles Cross-Linking symposium, CLICK HERE.

Attachments

(PNG FILE)

TrueTear™ - The New Dry Eye Therapy

TrueTear™ - The New Dry Eye Therapy

Created on: Thursday, June 01, 2017
Bryan Ross

 Do you have dry eye issues? TrueTear™ could be the product for you!

We are excited to be the first practice in Northern Virginia to offer TrueTear™ by Allergan. TrueTear™ is an intranasal neurostimulating device that helps increase tear production for those suffering with dry eyes without having to apply eye drops or artificial tears. This new innovative product is the first FDA-approved device that will help patients produce their own natural tears. Interested in learning more about TrueTear™? Give us a call at (877)234-2020
 
Additional information can be found here:

Attachments

(JPG FILE)

From Halloween to hospital? Avoid non-prescription costume contacts to save your sight! One teen’s cautionary tale, as seen on Good Morning America:

From Halloween to hospital? Avoid non-prescription costume contacts to save your sight! One teen’s cautionary tale, as seen on Good Morning America:

Created on: Friday, October 28, 2016
Bryan Ross

From Halloween to hospital? Avoid non-prescription costume contacts to save your sight! One teen’s cautionary tale, as seen on Good Morning America: http://bit.ly/1M2syhl

 

Using costume contacts to complete your Halloween look is great, as long as you have a prescription.

Using costume contacts to complete your Halloween look is great, as long as you have a prescription.

Created on: Monday, October 24, 2016
Bryan Ross

Using costume contacts to complete your Halloween look is great, as long as you have a prescription. Watch this video to learn what can happen if you don’t. http://bit.ly/1ByZhpA

 

Scratches, sores, infections…blindness. All of these can be caused by over-the-counter costume contacts.

Scratches, sores, infections…blindness. All of these can be caused by over-the-counter costume contacts.

Created on: Friday, October 07, 2016
Bryan Ross

 Scratches, sores, infections…blindness. All of these can be caused by over-the-counter costume contacts. Here’s why you need a prescription to make your eyes look like a zombie’s this Halloween: http://bit.ly/1KkMH0r

 

First FDA Approved Cross-Linking Procedures Are Performed on Patients in the U.S. with Progressive Keratoconus

First FDA Approved Cross-Linking Procedures Are Performed on Patients in the U.S. with Progressive Keratoconus

Created on: Friday, September 30, 2016
Bryan Ross

Logo
Sept. 28, 2016 04:01 UTC

First FDA Approved Cross-Linking Procedures Are Performed on Patients in the U.S. with Progressive Keratoconus

Avedro Shipping Photrexa® Viscous and Photrexa® to Ophthalmologists Nationwide

WALTHAM, Mass.--(BUSINESS WIRE)-- Avedro, Inc., an ophthalmic pharmaceutical and medical device company, is now shipping Photrexa Viscous and Photrexa, the drugs used in corneal cross-linking procedures with the KXL System. On April 15, 2016, Avedro received approval from the U.S. Food and Drug Administration (FDA) for Photrexa Viscous, Photrexa and the KXL System used in corneal collagen cross-linking for the treatment of progressive keratoconus. Subsequently on July 15, 2016, the company received U.S. FDA approval for the products’ second indication—for the treatment of corneal ectasia following refractive surgery.

“This is an exciting time in ophthalmology,” said Reza Zadno, PhD, recently appointed CEO for Avedro. “We are proud to announce that FDA approved cross-linking treatments are now a reality, and our Photrexa drug products are now available. Clinicians have already started to treat their patients in the U.S. who are suffering from progressive keratoconus or corneal ectasia.”

Rajesh Rajpal, MD, Chief Medical Officer for Avedro and a practicing cornea specialist at See Clearly Vision Group, added, “We were thrilled to treat our first patients after FDA approval last week in my practice. Avedro shipped the Photrexa products to over 50 locations in the U.S. over the last week, with more shipping each day, and practices are now treating patients. This marks a tremendous milestone and offers new hope to patients in the U.S., to help with their vision challenges and to treat these sight-threatening diseases.”

“Avedro’s product launch has been highly anticipated by the keratoconus community as patients can now receive the only FDA-approved cross-linking treatment available in the U.S.,” said Mary Prudden, Executive Director for the National Keratoconus Foundation. “The timing is ideal as we prepare for the first World Keratoconus Day taking place on November 10th.”

Corneal collagen cross-linking with Avedro’s Photrexa Viscous, Photrexa and the KXL system is the first and only cross-linking therapy approved by the FDA. Patients should consult their ophthalmologist to determine if corneal cross-linking is right for them. Patients and families can locate an ophthalmologist performing this procedure using the “Find a Physician” tool on Avedro’s website.

What are Photrexa Viscous and Photrexa?
PHOTREXA VISCOUS and PHOTREXA are photoenhancers indicated for use with the KXL System in corneal collagen cross-linking for the treatment of progressive keratoconus and corneal ectasia following refractive surgery.

Important Safety Information
In progressive keratoconus patients, the most common ocular adverse reactions were corneal opacity (haze), punctate keratitis, corneal striae, corneal epithelium defect, eye pain, reduced visual acuity, and blurred vision.

In corneal ectasia patients, the most common ocular adverse reactions were corneal opacity (haze), corneal epithelium defect, corneal striae, dry eye, eye pain, punctate keratitis, photophobia, reduced visual acuity, and blurred vision.

Ulcerative keratitis can occur, and patients should be monitored for resolution of epithelial defects. It is not known if CXL is safe and effective in pediatric patients below the age of 14 years.

Please see full Prescribing Information by clicking here: http://avedro.com/wp-content/uploads/dlm_uploads/13597/

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch or call 1-800-FDA-1088.

About Keratoconus
Keratoconus is a progressive thinning and distortion of the cornea. It is the most common corneal dystrophy in the US, affecting approximately one in every 2,000 Americans1or approximately 170,000 people in the US. Keratoconus causes the cornea to bulge from its normal symmetric domelike smooth optical shape, creating an abnormal curvature that changes the cornea's optics, producing blurred and distorted vision that is difficult to correct with spectacle lenses. This progressive thinning and weakening can result in significant visual loss and may lead to corneal transplants.

About Corneal Ectasia
Corneal ectasia, a non-inflammatory condition marked by progressive corneal steepening and thinning, is a rare but serious complication of vision correction procedures. The condition can begin within a week of surgery or after several years and is associated with worsening best-uncorrected visual acuity, an increase in ocular aberrations, and decreasing best-corrected distance visual acuity.

About Avedro, Inc.
Avedro is a privately held pharmaceutical and medical device company advancing the science and technology of corneal cross-linking and refractive correction.

Avedro’s Photrexa Viscous, Photrexa and KXL products are approved for sale in the United States for the treatment of progressive keratoconus and corneal ectasia following refractive surgery. Avedro’s products sold outside of the United States include capital equipment such as the UV-X devices, the KXL® and Mosaic™ Systems, and related proprietary pharmaceuticals such as the VibeX® and MedioCROSS® formulations. Avedro distributes its products in countries outside of the United States through a network of ophthalmic medical device distributors.

1 National Eye Institute (NEI). Facts About The Cornea and Corneal Disease. http://www.nei.nih.gov/health/cornealdisease/#12

 

Contacts

Avedro, Inc.
David Iannetta, 1-844-528-3376
info@avedro.com
or
Media:
BioComm Network, Inc.
Tad Heitmann, 949-494-3140
theitmann@biocommnetwork.com
or
BioComm Network, Inc.
Michele Gray, 917-449-9250
michele_gray@me.com

 

Source: Avedro, Inc.

 

First patient to have Collagen Cross-Linking after FDA approval.

First patient to have Collagen Cross-Linking after FDA approval.

Created on: Thursday, September 22, 2016
Bryan Ross

First patient to have Collagen Cross-Linking after FDA approval with Dr. Rajesh Rajpal.  Congratulations to Dr. Rajpal and the staff at See Clearly Vision!

 

 

What you should know about swimming and your eyes

What you should know about swimming and your eyes

Created on: Wednesday, August 24, 2016
Bryan Ross

Whether you enjoy a leisurely dip in a hotel pool or compete in the Olympic 200 meter freestyle, you may be familiar with the stinging, burning and redness of “swimmer’s eye.” While swimming is a great form of exercise and a relaxing way to cool down, it can be hard on your eyes.....www.aao.org/eye-health/tips-prevention/swimming-contacts-your-eyes

 

New Collagen Cross-Linking Indication in US

New Collagen Cross-Linking Indication in US

Created on: Thursday, July 28, 2016
Bryan Ross

In this edition of EyewireTV, Dr. Rajesh Rajpal discusses the recent FDA approval for a second indication of Collagen Cross-Linking for the treatment of Corneal Ectasia following Refractive Surgery.  For further information and to watch the video, please visit:

eyewiretoday.com/tv/eyewiretv-tecnis-symfony-iol-fda-approved-new-cross-linking-indication-in-us/

 

Avedro Plots Future of Corneal Cross-Linking

Avedro Plots Future of Corneal Cross-Linking

Created on: Friday, July 08, 2016
Bryan Ross

Just about two weeks after getting Food and Drug Administration (FDA) clearance for its corneal crosslinking platform, Avedro Chief Medical Officer Rajesh K. Raipal, MD, outlined the company’s next steps to advance its position in the crosslinking space during the Ophthalmology Innovations Showcase at OIS@ASCRS 2016.

http://ois.net/avedro-plots-future-of-corneal-cross-linking/

 

What you need to know about Corneal Collagen Cross-Linking

What you need to know about Corneal Collagen Cross-Linking

Created on: Thursday, June 16, 2016
Bryan Ross

April 18th, 2016 was a life-changing day for people living with keratoconus in the USA; corneal collagen crosslinking, the revolutionary treatment that's been performed in Europe since 1999, was finally approved by the FDA. Keratoconus affects as many as 1 in every 500 people, causing potentially severe vision loss.  But it's progression and causes are poorly understood. During the disease process, the cornea tissue thins and weakens, causing the cornea to prolapse forward like a steepening mountain.  The resulting warpage and associated scarring wrecks havoc on vision, often requiring severely invasive procedures like full thickness corneal transplant as the condition worsens. In corneal collagen crosslinking, the goal is to stop the progression of keratoconus while the damage is still mild and vision is still usable, long before more aggressive surgical interventions would be needed. Using riboflavin and UV light, doctors are able to strengthen the connections of the collagen fibers of the cornea so that they hold tighter and stronger together, locking the cornea in place. 

 
Because the procedure is so new here in the USA, most people living with keratoconus are being offered corneal crosslinking as a surgical option for the first time.  Confusion about the procedure and its possible outcomes abounds.  I interviewed Dr. Christine B. Wisecarver, an optometrist practicing at See Clearly Vision who manages the care of patients before and after corneal crosslinking surgery, and their surgical coordinator, Irina Price about what patients need to know before corneal crosslinking.


 
Who do you consider a good candidate for corneal collagen crosslinking? There has been a paradigm shift in the management of keratoconus patients. Patients with evidence of keratoconus should now be treated with collagen crosslinking as soon as possible. Once they have been cross linked, patients should be managed with spectacles and contact lenses as needed. Collagen crosslinking is currently FDA approved for the treatment of progressive keratoconus only. It is not currently covered by any insurance company, and much like refractive surgery, is considered at the discretion of the doctor. Candidates for crosslinking are patients who have been diagnosed with keratoconus and are cleared for crosslinking by their physician.

 
At what age would you consider treating a young patient with keratoconus that was advancing rapidly? Safety and efficacy has not been established in patients under the age of 14 years old.

 
What can a patient expect visually from the procedure? Crosslinking helps prevent progression of the disease. It does not reverse keratoconus, and is not a refractive procedure (meaning it will not correct a patient's vision). Some patients get a mild flattening effect as they heal, but this does not happen for every patient. All crosslinking patients are advised that if they are wearing specialty contact lenses before the procedure, they will likely need them following their treatment. Since the cornea will be changing in the first 6 months after the procedure, a new refraction and contact lens refit will be needed.
Corneal collagen crosslinking does not improve vision in keratoconus patients. The sole purpose of crosslinking is to halt the progressive steepening and thinning of the cornea. Having said that, it is currently the ONLY treatment that can reduce and ultimately halt the progression of the disease.

 
What can a patient expect of the procedure itself? The procedure is about 1 hour long with drops instilled every 2 minutes and UV light exposure to the cornea for 30 minutes. A bandage contact lens is then placed on the eye to allow the surface cells to heal. After 5 to 7 days, the bandage contact lens is removed. The healing time is very similar to PRK (except here patients get drops and UV light instead of laser). Patients may be uncomfortable for the first 3 days while the surface is healing. Antibiotic and steroid eye drops are used in the immediate post-operative period. Using a copious amount of preservative-free artificial tears can help to speed up the healing process.

 
How long after the procedure does it take to see results? Patients will likely not appreciate any visual result from treatment. The cornea usually stabilizes (i.e., curvature changes and prescription changes) by the 6 month mark. After that time, topography can be used to demonstrate that the procedure has helped to slow the progression of keratoconus.

 
Besides keratoconus, are there other conditions you would treat with corneal crosslinking? There is no current FDA approval for treatment with corneal crosslinking beyond that of progressive keratoconus. Off-label treatments for corneal disorders other than keratoconus (for example, corneal ectasia following refractive surgery), are at the discretion of the corneal specialist.

 
What do you see for the future using corneal crosslinking technology? Future indications for collagen crosslinking are currently being studied in the US and abroad. One possible indication is LASIK/PRK Xtra (crosslinking at the time of refractive surgery) to prevent post-refractive ectasia in higher risk patients like high myopes, young patients, and those with thin corneas. Additionally, surgeons are exploring targeted crosslinking where the aim is to achieve a visually improving refractive result in addition to preventing progression of keratoconus.  Combination treatments like these, and the use of crosslinking for patients at risk for corneal perforation are areas in which cross linking may play a role in the future.

 

 
 

 

Posted by at  

 

FDA Approval for Collagen Cross-Linking

FDA Approval for Collagen Cross-Linking

Created on: Saturday, May 28, 2016
See Clearly Vision

See Clearly Vision is proud to announce the FDA approval for Collagen Cross-Linking for progressive Keratoconus.  Since the induction of Collagen Cross-Linking in the United States, Dr. Rajesh Rajpal, Dr. Khoa Hoang, Dr. Christine Wisecarver, Dr. Dawn Williams and the staff at See Clearly Vision conducted rigorous clinical trials and have provided their expertise to lead the way for this highly anticipated procedure. We look forward to being one of the first in the industry to provide this groundbreaking treatment to progressive Keratoconus patients. 

Please visit the link http://www.businesswire.com/news/home/20160418006610/en/ for additional information about Collagen Cross-Linking.  To see if Collagen Cross-Linking can benefit you, please feel free to call us at (703) 827-5454 to schedule an appointment for an evaluation.

Dr. Rajesh Rajpal Selected As Ocular Surgery News\' Premier Surgeon 300

Dr. Rajesh Rajpal Selected As Ocular Surgery News' Premier Surgeon 300

Created on: Friday, May 27, 2016
See Clearly Vision

See Clearly vision is proud to announce that Rajesh K. Rajpal, M.D. has been named to the prestigious Ocular Surgery News’ Premier Surgeon 300 – an elite group of premium refractive cataract surgeons that prove to be innovators in the field.

What is a Premier Surgeon?  The Premier Surgeon 300 is a list of premium refractive cataract surgeons the editors and publisher have identified as leading innovators in the field of refractive cataract surgery. These surgeons work to educate their colleagues, innovate by developing novel technologies and techniques to advance the premium practice or perform a high volume of premium refractive cataract surgery.

To view the full Premier Surgeon 300 list click here.

Top Doctor 2015 Award

Top Doctor 2015 Award

Created on: Tuesday, March 22, 2016
See Clearly Vision

 

In the News: See Clearly Vision leads the way as first in the nation to forward science and medicine in ophthalmology

In the News: See Clearly Vision leads the way as first in the nation to forward science and medicine in ophthalmology

Created on: Thursday, November 14, 2013
See Clearly Vision

 Avedro Announces the Start of Two New US FDA Trials for Accelerated Crosslinking

Lasik with Cross‐linking and Pulsed Accelerated Cross‐linking

Waltham, Massachusetts, USA, November 12, 2013 – Avedro Inc., a Bostonbased ophthalmic medical device and pharmaceutical company, announces today that the first patients have been treated in two new US clinical trials: Lasik with Crosslinking and Pulsed Accelerated Crosslinking.

Lasik with crosslinking is a two minute procedure performed in conjunction with a standard Lasik procedure to investigate if crosslinking following Lasik reduces regression of refractive outcome in patients with hyperopia or hyperopic astigmatism. Lasik with crosslinking (Lasik Xtra®) is currently approved outside the United States and has been used successfully in more than 75,000 Lasik procedures.

Rajesh K. Rajpal, MD, of See Clearly Vision in the Washington, DC area and a member of Avedro’s Medical Advisory Board stated, “During the past two years I’ve had the opportunity to perform Lasik Xtra with ophthalmic colleagues outside of the United States and have been impressed with the outcomes I witnessed. As the first refractive surgeon to perform Lasik Xtra in the United States in Avedro’s new FDA trial, I am looking forward to evaluating Lasik Xtra in this controlled clinical study in the US.”

“Outside of the United States, Lasik Xtra is becoming increasingly embraced by refractive surgeons and patients alike,” said David Muller, PhD, CEO of Avedro. “Our international experience with Hyperopic Lasik has been very encouraging and we look forward to repeating those results in our new Lasik Xtra FDA trial.”

Avedro’s second new FDA trial for Pulsed Accelerated Crosslinking investigates pulsed UVA light to treat keratoconus. Avedro’s science team discovered that pulsed, rather than continuous UVA light, is important when using higher power accelerated crosslinking, such as that available with Avedro’s KXL® System.

“I am pleased to be the first US surgeon to begin enrolling keratoconus patients with Avedro’s pulsed accelerated crosslinking using its KXL System,” said Michael Raizman, MD, Ophthalmic Consultants of Boston, and a member of Avedro’s Medical Advisory Board. “Avedro’s pulsed accelerated crosslinking is already being routinely used internationally with excellent outcomes.”

“US surgeons are eagerly awaiting the possibility of both Accelerated Crosslinking and Lasik Xtra,” Peter Hersh, MD, Hersh Vision Group, Teaneck, NJ and Avedro Medical Monitor. “We see the results that our international colleagues are obtaining, and we are pleased to have begun US trials to provide access to these procedures for select US patients.”

Further information about the Lasik Xtra trial and the Pulsed Accelerated Crosslinking trial can be found at www.clinicaltrials.gov.

About Avedro, Inc.

Avedro is a privately held medical device and pharmaceutical company advancing the science and technology of corneal crosslinking and refractive correction. Avedro’s products include capital equipment and related single dose pharmaceuticals. Those products are currently used in a procedure known as Lasik Xtra. Over 75,000 surgeries have been successfully performed outside the US using Avedro’s KXL System. The KXL System’s accelerated crosslinking, in combination with its pharmaceuticals, is also used to treat several important and debilitating ophthalmic pathologies outside the United States.

Avedro distributes its products in 62 countries through 33 ophthalmic distributors with 115 representatives. Avedro products that have received CE Mark include: the KXLTM II System for performing PiXLTM, the KXL System for performing Lasik Xtra® and Accelerated Crosslinking, and the Avedro family of proprietary single dose pharmaceutical formulations.

Avedro’s KXL System and single dose pharmaceutical products are currently being used in three Phase III US clinical trials involving over 100 US clinical sites. Avedro products are not for sale in the US.

Contact:
Kristen Gleason Avedro, Inc.; kgleason@avedro.com; 781
7683400 

Tips for Tackling Conjunctivitis

Tips for Tackling Conjunctivitis

Created on: Thursday, September 05, 2013
See Clearly Vision

For the full article, please click the link below

https://www.seeclearly.com/pdfs/AUG15_OT_Rajpal.pdf

Blog Home